| Title： | Consensus on the Standardization of Mycobacterium tuberculosis Drug Susceptibility Testing by Broth Microdilution plate Method in China |
| Edition： | Original |
| Classification： | Experts consensus |
| Field： | Comprehensive guideline |
| Countries and regions： | China |
| Guidelines users： | Doctors and laboratory personnel from medical system and disease prevention and control institutions at all levels. |
| Evidence classification method： | The recommendations were attained using the Delphi voting method, where all experts involved in the consensus development voted and provided feedback. A consensus with an approval rate of ≥ 90% is classified as a strong recommendation, 75% to < 90% as a weak recommendation, and < 75% as no recommendation. The drafting committee revised the document based on the feedback, and the final version was approved by the steering committee after review. |
| Development unit： | Fangyou Yu |
| Registration time: | 2024-10-24 |
| Registration number： | PREPARE-2024CN048 |
| Purpose of the guideline: | Tuberculosis (TB), especially drug-resistant TB, is a severe public health challenge in China. Current diagnostic methods, such as phenotypic drug susceptibility testing (DST) and molecular diagnostics, have limitations either in providing accurate drug resistance profiles or detecting new resistance genes. The broth microdilution plate method (BMD plate), which measures minimum inhibitory concentrations (MICs), is gaining attention for its ability to provide more detailed drug susceptibility data, making it more effective for guiding treatment. To standardize the use of BMD in managing drug-resistant TB in China, a consensus has been developed to offer unified guidelines. |
